Development of gene therapy for treatment of age-related macular degeneration

Acta Ophthalmologica

Volumn 92, Issue THESIS 3, 2014, Pages 1-38

  Askou, Anne Louise ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; MICRORNA; PARVOVIRUS VECTOR; PIGMENT EPITHELIUM DERIVED FACTOR; SHORT HAIRPIN RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VIRUS PROTEIN; SMALL INTERFERING RNA; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; DISEASE COURSE; DOWN REGULATION; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; ENZYME ASSAY; EXUDATIVE MACULAR DEGENERATION; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GENE STRUCTURE; GENE THERAPY; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HINDLIMB; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; LEG MUSCLE; MUTAGENESIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA BLOOD FLOW; RETINA CELL; RETINA MACULA AGE RELATED DEGENERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; RNA INTERFERENCE; SUBRETINAL NEOVASCULARIZATION; VEGF GENE; VIRAL GENE DELIVERY SYSTEM; VIRUS LOAD; VITELLIFORM MACULAR DYSTROPHY 2 PROMOTER; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHOROIDAL NEOVASCULARIZATION; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; MACULAR DEGENERATION; MALE; MOUSE; PROCEDURES;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; MACULAR DEGENERATION; MALE; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903125763     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12452     Document Type: Article

References (250)

1. Aagaard LA, Zhang J, von Eije KJ, Li H, Saetrom P, Amarzguioui M, &, Rossi JJ, (2008): Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther 15: 1536-1549.
2. Abdelsalam A, Del Priore L, &, Zarbin MA, (1999): Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Surv Ophthalmol 44: 1-29. (Pubitemid 29378350)
3. Abraham JA, Mergia A, Whang JL, Tumolo A, Friedman J, Hjerrild KA, Gospodarowicz D, &, Fiddes JC, (1986): Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 233: 545-548. (Pubitemid 16019907)
4. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, &, Yeo KT, (1994): Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118: 445-450. (Pubitemid 24307211)
5. Aiello LP, Avery RL, Arrigg PG, et al. (1994): Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487. (Pubitemid 24356306)
6. Allocca M, Mussolino C, Garcia-Hoyos M, et al. (2007): Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol 81: 11372-11380. (Pubitemid 47536108)
7. Alon T, Hemo I, Itin A, Pe'er J, Stone J, &, Keshet E, (1995): Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1: 1024-1028.
8. Apolonia L, Waddington SN, Fernandes C, et al. (2007): Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 15: 1947-1954. (Pubitemid 350011734)
9. AREDS (2001): A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119: 1417-1436.
10. Ashikari M, Tokoro M, Itaya M, Nozaki M, &, Ogura Y, (2010): Suppression of laser-induced choroidal neovascularization by nontargeted siRNA. Invest Ophthalmol Vis Sci 51: 3820-3824.
11. Auricchio A, Kobinger G, Anand V, Hildinger M, O'Connor E, Maguire AM, Wilson JM, &, Bennett J, (2001): Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 10: 3075-3081. (Pubitemid 34083493)
12. Auricchio A, Behling KC, Maguire AM, O'Connor EM, Bennett J, Wilson JM, &, Tolentino MJ, (2002): Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther 6: 490-494. (Pubitemid 35214870)
13. Bai YJ, Huang LZ, Xu XL, Du W, Zhou AY, Yu WZ, &, Li XX, (2012): Polyethylene glycol-modified pigment epithelial-derived factor: new prospects for treatment of retinal neovascularization. J Pharmacol Exp Ther 342: 131-139.
14. Bainbridge JW, Smith AJ, Barker SS, et al. (2008): Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231-2239. (Pubitemid 351724452)
15. Balaggan KS, &, Ali RR, (2012): Ocular gene delivery using lentiviral vectors. Gene Ther 19: 145-153.
16. Bartel DP, (2004): MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
17. Bates DO, Cui TG, Doughty JM, et al. (2002): VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 62: 4123-4131. (Pubitemid 34791084)
18. Bayer M, Kantor B, Cockrell A, Ma H, Zeithaml B, Li X, McCown T, &, Kafri T, (2008): A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. Mol Ther 16: 1968-1976.
19. Becerra SP, &, Notario V, (2013): The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential. Nat Rev Cancer 13: 258-271.
20. Becerra SP, Fariss RN, Wu YQ, Montuenga LM, Wong P, &, Pfeffer BA, (2004): Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution. Exp Eye Res 78: 223-234. (Pubitemid 38077229)
21. Bek T, Bertelsen T, Ehlers N, &, Fagerholm P, (2004): Oftalmologi-Nordisk lærebok og atlas. John Grieg. Bergen, Norway.
22. Benhar I, London A, &, Schwartz M, (2012): The privileged immunity of immune privileged organs: the case of the eye. Front Immunol 3: 296.
23. Bennett J, Ashtari M, Wellman J, et al. (2012): AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 4: 120ra115.
24. Berge M, Bonnin P, Sulpice E, et al. (2010): Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am J Pathol 177: 3192-3201.
25. Bergers G, Brekken R, McMahon G, et al. (2000): Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744.
26. Bernatchez PN, Soker S, &, Sirois MG, (1999): Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J Biol Chem 274: 31047-31054.
27. Binley K, Widdowson PS, Kelleher M, et al. (2012): Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat((R)), for age-related macular degeneration. Hum Gene Ther 23: 980-991.
28. Bird AC, (2010): Therapeutic targets in age-related macular disease. J Clin Investig 120: 3033-3041.
29. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. (1999): Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 155: 421-428. (Pubitemid 29370392)
30. Boudreau RL, Monteys AM, &, Davidson BL, (2008): Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 14: 1834-1844.
31. Boudreau RL, Martins I, &, Davidson BL, (2009): Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 17: 169-175.
32. Brafman A, Mett I, Shafir M, et al. (2004): Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest Ophthalmol Vis Sci 45: 3796-3805. (Pubitemid 39298599)
33. Brennecke J, Stark A, Russell RB, &, Cohen SM, (2005): Principles of microRNA-target recognition. PLoS Biol 3: e85.
34. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, &, Iggo R, (2003): Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34: 263-264. (Pubitemid 36792856)
35. Bruewer AR, Mowat FM, Bartoe JT, Boye SL, Hauswirth WW, &, Petersen-Jones SM, (2013): Evaluation of lateral spread of transgene expression following subretinal AAV-mediated gene delivery in dogs. PLoS One 8: e60218.
36. Brummelkamp TR, Bernards R, &, Agami R, (2002): A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553. (Pubitemid 34408678)
37. Campochiaro PA, (2013): Ocular neovascularization. J Mol Med (Berl) 91: 311-321.
38. Campochiaro PA, Nguyen QD, Shah SM, et al. (2006): Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 17: 167-176. (Pubitemid 43262032)
39. Cashman SM, Bowman L, Christofferson J, &, Kumar-Singh R, (2006): Inhibition of choroidal neovascularization by adenovirus-mediated delivery of short hairpin RNAs targeting VEGF as a potential therapy for AMD. Invest Ophthalmol Vis Sci 47: 3496-3504. (Pubitemid 351639716)
40. Cayouette M, Smith SB, Becerra SP, &, Gravel C, (1999): Pigment epithelium-derived factor delays the death of photoreceptors in mouse models of inherited retinal degenerations. Neurobiol Dis 6: 523-532. (Pubitemid 30036622)
41. Chen Y, Hu Y, Lu K, Flannery JG, &, Ma JX, (2007): Very low density lipoprotein receptor, a negative regulator of the wnt signaling pathway and choroidal neovascularization. J Biol Chem 282: 34420-34428. (Pubitemid 350159486)
42. Chung KH, Hart CC, Al-Bassam S, Avery A, Taylor J, Patel PD, Vojtek AB, &, Turner DL, (2006): Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res 34: e53.
43. Cohen T, Nahari D, Cerem LW, Neufeld G, &, Levi BZ, (1996): Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271: 736-741. (Pubitemid 26034921)
44. Cornu TI, &, Cathomen T, (2007): Targeted genome modifications using integrase-deficient lentiviral vectors. Mol Ther 15: 2107-2113. (Pubitemid 350148926)
45. Coutant F, Frenkiel MP, Despres P, &, Charneau P, (2008): Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One 3: e3973.
46. Crabb JW, Miyagi M, Gu X, et al. (2002): Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA 99: 14682-14687. (Pubitemid 35334544)
47. Dalkara D, Kolstad KD, Caporale N, Visel M, Klimczak RR, Schaffer DV, &, Flannery JG, (2009): Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther 17: 2096-2102.
48. Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH, Flannery JG, &, Schaffer DV, (2013): In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 5: 189ra176.
49. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, &, Bouck NP, (1999): Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285: 245-248. (Pubitemid 29329995)
50. Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, &, Lowe SW, (2005): Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 37: 1289-1295. (Pubitemid 41568715)
51. Du Q, Zhang X, Cardinal J, Cao Z, Guo Z, Shao L, &, Geller DA, (2009): Wnt/beta-catenin signaling regulates cytokine-induced human inducible nitric oxide synthase expression by inhibiting nuclear factor-kappaB activation in cancer cells. Cancer Res 69: 3764-3771.
52. Ehlert EM, Eggers R, Niclou SP, &, Verhaagen J, (2010): Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. BMC Neurosci 11: 20.
53. Esser P, Heimann K, &, Wiedemann P, (1993): Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations. Br J Ophthalmol 77: 731-733. (Pubitemid 23326062)
54. Fedorov Y, Anderson EM, Birmingham A, et al. (2006): Off-target effects by siRNA can induce toxic phenotype. RNA 12: 1188-1196. (Pubitemid 43990544)
55. Ferris FL III, Fine SL, &, Hyman L, (1984): Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102: 1640-1642. (Pubitemid 15204559)
56. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, &, Mello CC, (1998): Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811. (Pubitemid 28099681)
57. Fisher SA, Abecasis GR, Yashar BM, et al. (2005): Meta-analysis of genome scans of age-related macular degeneration. Hum Mol Genet 14: 2257-2264. (Pubitemid 41418025)
58. Folkman J, (1995): Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
59. Francis PJ, Hamon SC, Ott J, Weleber RG, &, Klein ML, (2009): Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss. J Med Genet 46: 300-307.
60. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, &, Werner S, (1995): Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 270: 12607-12613.
61. Frank RN, Amin RH, Eliott D, Puklin JE, &, Abrams GW, (1996): Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 122: 393-403. (Pubitemid 26300056)
62. Friedman E, (1997): A hemodynamic model of the pathogenesis of age-related macular degeneration. Am J Ophthalmol 124: 677-682.
63. Friedman E, (2000): The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol 130: 658-663.
64. Fritsche LG, Chen W, Schu M, et al. (2013): Seven new loci associated with age-related macular degeneration. Nat Genet, 45: 433-439, 439e431-432.
65. Garba AO, &, Mousa SA, (2010): Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis 2: 75-83.
66. Gaudry M, Bregerie O, Andrieu V, El Benna J, Pocidalo MA, &, Hakim J, (1997): Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 90: 4153-4161. (Pubitemid 27484071)
67. Gehlbach P, Demetriades AM, Yamamoto S, et al. (2003): Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther 14: 129-141. (Pubitemid 36422598)
68. Geneser F, Dørup J, &, Hansen MS, (2002): Histologi-På Molekylærbiologisk Grundlag. Munksgaard. Copenhagen, Denmark.
69. Gerber HP, Condorelli F, Park J, &, Ferrara N, (1997): Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 272: 23659-23667. (Pubitemid 27410939)
70. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, &, Ferrara N, (2001): Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276: 3222-3230.
71. Gold B, Merriam JE, Zernant J, et al. (2006): Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 38: 458-462.
72. Gradl D, Kuhl M, &, Wedlich D, (1999): The Wnt/Wg signal transducer beta-catenin controls fibronectin expression. Mol Cell Biol 19: 5576-5587. (Pubitemid 29339915)
73. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, &, Guyer DR, (2004): Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816. (Pubitemid 40051904)
74. Green WR, &, Key SN III, (1977): Senile macular degeneration: a histopathologic study. Trans Am Ophthalmol Soc 75: 180-254.
75. Green WR, &, Wilson DJ, (1986): Choroidal neovascularization. Ophthalmology 93: 1169-1176. (Pubitemid 17211514)
76. Grimm D, Streetz KL, Jopling CL, et al. (2006): Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541. (Pubitemid 44050158)
77. Grimm D, Wang L, Lee JS, Schurmann N, Gu S, Borner K, Storm TA, &, Kay MA, (2010): Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Investig 120: 3106-3119.
78. Grossniklaus HE, &, Green WR, (1998): Histopathologic and ultrastructural findings of surgically excised choroidal neovascularization. Submacular Surgery Trials Research Group. Arch Ophthalmol 116: 745-749. (Pubitemid 28292727)
79. Grossniklaus HE, Cingle KA, Yoon YD, Ketkar N, L'Hernault N, &, Brown S, (2000): Correlation of histologic 2-dimensional reconstruction and confocal scanning laser microscopic imaging of choroidal neovascularization in eyes with age-related maculopathy. Arch Ophthalmol 118: 625-629. (Pubitemid 30327338)
80. Gu X, Meer SG, Miyagi M, Rayborn ME, Hollyfield JG, Crabb JW, &, Salomon RG, (2003): Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem 278: 42027-42035. (Pubitemid 37310467)
81. Gu L, Chen H, Tuo J, Gao X, &, Chen L, (2010): Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA. Exp Eye Res 91: 433-439.
82. Gu S, Jin L, Zhang Y, Huang Y, Zhang F, Valdmanis PN, &, Kay MA, (2012): The loop position of shRNAs and pre-miRNAs is critical for the accuracy of dicer processing in vivo. Cell 151: 900-911.
83. Guerrin M, Moukadiri H, Chollet P, Moro F, Dutt K, Malecaze F, &, Plouet J, (1995): Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol 164: 385-394.
84. Gulcan HG, Alvarez RA, Maude MB, &, Anderson RE, (1993): Lipids of human retina, retinal pigment epithelium, and Bruch's membrane/choroid: comparison of macular and peripheral regions. Invest Ophthalmol Vis Sci 34: 3187-3193. (Pubitemid 23309058)
85. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, &, Mullins RF, (2001): An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 20: 705-732. (Pubitemid 32918285)
86. Haines JL, Schnetz-Boutaud N, Schmidt S, et al. (2006): Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci 47: 329-335. (Pubitemid 46780832)
87. Hammond SM, Bernstein E, Beach D, &, Hannon GJ, (2000): An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404: 293-296. (Pubitemid 30163547)
88. Harman D, (1956): Aging: a theory based on free radical and radiation chemistry. J Gerontol 11: 298-300.
89. Harmey JH, Dimitriadis E, Kay E, Redmond HP, &, Bouchier-Hayes D, (1998): Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol 5: 271-278. (Pubitemid 28249320)
90. Harper SJ, &, Bates DO, (2008): VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8: 880-887.
91. Hassel D, Cheng P, White MP, et al. (2012): MicroRNA-10 regulates the angiogenic behavior of zebrafish and human endothelial cells by promoting vascular endothelial growth factor signaling. Circ Res 111: 1421-1433.
92. Hauswirth WW, Aleman TS, Kaushal S, et al. (2008): Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19: 979-990.
93. Heale BS, Soifer HS, Bowers C, &, Rossi JJ, (2005): siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res 33: e30.
94. Heckenlively JR, Hawes NL, Friedlander M, Nusinowitz S, Hurd R, Davisson M, &, Chang B, (2003): Mouse model of subretinal neovascularization with choroidal anastomosis. Retina 23: 518-522. (Pubitemid 37071966)
95. Heiba IM, Elston RC, Klein BE, &, Klein R, (1994): Sibling correlations and segregation analysis of age-related maculopathy: the Beaver Dam Eye Study. Genet Epidemiol 11: 51-67. (Pubitemid 24089911)
96. Heier JS, Antoszyk AN, Pavan PR, et al. (2006): Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 113: 633.e1-633.e4.
97. Helvik SA, Snove O Jr, &, Saetrom P, (2007): Reliable prediction of Drosha processing sites improves microRNA gene prediction. Bioinformatics 23: 142-149. (Pubitemid 46189602)
98. Hildebrand GD, &, Fielder AR, (2011): Anatomy and physiology of the retina. In:, Reynolds JD, &, Olitsky SE, (eds). Pediatric Retina, p. 39-65. Springer, Berlin, Germany.
99. Holash J, Davis S, Papadopoulos N, et al. (2002): VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398. (Pubitemid 34920936)
100. Holmes DI, &, Zachary I, (2005): The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol 6: 209.
101. Honda M, Sakamoto T, Ishibashi T, Inomata H, &, Ueno H, (2000): Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther 7: 978-985. (Pubitemid 30386663)
102. Hou X, Kumar A, Lee C, et al. (2010): PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets. Proc Natl Acad Sci USA 107: 12216-12221.
103. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, &, Leung DW, (1991): The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5: 1806-1814.
104. Huang V, Qin Y, Wang J, Wang X, Place RF, Lin G, Lue TF, &, Li LC, (2010): RNAa is conserved in mammalian cells. PLoS One 5: e8848.
105. Huang H, Parlier R, Shen JK, Lutty GA, &, Vinores SA, (2013): VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV. PLoS One 8: e71808.
106. Hussain AA, Starita C, Hodgetts A, &, Marshall J, (2010): Macromolecular diffusion characteristics of ageing human Bruch's membrane: implications for age-related macular degeneration (AMD). Exp Eye Res 90: 703-710.
107. Ideno J, Mizukami H, Kakehashi A, et al. (2007): Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model. Int J Mol Med 19: 75-79.
108. Igarashi T, Miyake K, Masuda I, Takahashi H, &, Shimada T, (2010): Adeno-associated vector (type 8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model. Hum Gene Ther 21: 631-637.
109. Igarashi T, Miyake N, Fujimoto C, Yaguchi C, Iijima O, Shimada T, Takahashi H, &, Miyake K, (2014): Adeno-associated virus type 8 vector-mediated expression of siRNA targeting vascular endothelial growth factor efficiently inhibits neovascularization in a murine choroidal neovascularization model. Mol Vis 20: 488-496.
110. Jacobson SG, Cideciyan AV, Ratnakaram R, et al. (2012): Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 130: 9-24.
111. Kachi S, Binley K, Yokoi K, et al. (2009): Equine infectious anemia viral vector-mediated codelivery of endostatin and angiostatin driven by retinal pigmented epithelium-specific VMD2 promoter inhibits choroidal neovascularization. Hum Gene Ther 20: 31-39.
112. Kaplan HJ, Leibole MA, Tezel T, &, Ferguson TA, (1999): Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med 5: 292-297. (Pubitemid 29124364)
113. Karali M, Manfredi A, Puppo A, et al. (2011): MicroRNA-restricted transgene expression in the retina. PLoS One 6: e22166.
114. Kariko K, Buckstein M, Ni H, &, Weissman D, (2005): Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23: 165-175. (Pubitemid 41169286)
115. Kawazoe Y, Sugita S, Keino H, Yamada Y, Imai A, Horie S, &, Mochizuki M, (2012): Retinoic acid from retinal pigment epithelium induces T regulatory cells. Exp Eye Res 94: 32-40.
116. Kendall RL, &, Thomas KA, (1993): Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90: 10705-10709. (Pubitemid 23347111)
117. Killingsworth MC, Sarks JP, &, Sarks SH, (1990): Macrophages related to Bruch's membrane in age-related macular degeneration. Eye (Lond) 4 (Pt 4): 613-621. (Pubitemid 20376823)
118. Kim VN, &, Nam JW, (2006): Genomics of microRNA. Trends Genet 22: 165-173. (Pubitemid 43290020)
119. Kim I, Ryan AM, Rohan R, Amano S, Agular S, Miller JW, &, Adamis AP, (1999): Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 40: 2115-2121. (Pubitemid 29365177)
120. Klein R, Klein BE, &, Linton KL, (1992): Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99: 933-943.
121. Klein R, Klein BE, Jensen SC, &, Meuer SM, (1997): The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 104: 7-21. (Pubitemid 27081937)
122. Klein R, Peto T, Bird A, &, Vannewkirk MR, (2004): The epidemiology of age-related macular degeneration. Am J Ophthalmol 137: 486-495. (Pubitemid 38328641)
123. Klein R, Meuer SM, Knudtson MD, Iyengar SK, &, Klein BE, (2008): The epidemiology of retinal reticular drusen. Am J Ophthalmol 145: 317-326.
124. Kleinman ME, Yamada K, Takeda A, et al. (2008): Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452: 591-597. (Pubitemid 351483358)
125. Kleinman ME, Kaneko H, Cho WG, et al. (2012): Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Mol Ther 20: 101-108.
126. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, &, de Jong PT, (1997): Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 81: 154-162. (Pubitemid 27092496)
127. Konopatskaya O, Churchill AJ, Harper SJ, Bates DO, &, Gardiner TA, (2006): VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis 12: 626-632. (Pubitemid 43786776)
128. Kur J, Newman EA, &, Chan-Ling T, (2012): Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. Prog Retin Eye Res 31: 377-406.
129. Kurihara T, Westenskow PD, Bravo S, Aguilar E, &, Friedlander M, (2012): Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Investig 122: 4213-4217.
130. Kvanta A, Algvere PV, Berglin L, &, Seregard S, (1996): Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37: 1929-1934. (Pubitemid 26324159)
131. Lai CM, Shen WY, Brankov M, et al. (2005): Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther 12: 659-668. (Pubitemid 41350147)
132. Lai CM, Estcourt MJ, Himbeck RP, et al. (2012): Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Ther 19: 999-1009.
133. Lai CF, Chen CY, &, Au LC, (2013): Comparison between the repression potency of siRNA targeting the coding region and the 3a€-untranslated region of mRNA. Biomed Res Int 2013: 637850.
134. Lambert V, Munaut C, Jost M, Noel A, Werb Z, Foidart JM, &, Rakic JM, (2002): Matrix metalloproteinase-9 contributes to choroidal neovascularization. Am J Pathol 161: 1247-1253.
135. Lambert V, Lecomte J, Hansen S, Blacher S, Gonzalez ML, Struman I, Sounni NE, Rozet E, de Tullio P, Foidart JM, Rakic JM, &, Noel A, (2013): Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. Nat Protoc 8: 2197-2211.
136. Lange T, Guttmann-Raviv N, Baruch L, Machluf M, &, Neufeld G, (2003): VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells. J Biol Chem 278: 17164-17169. (Pubitemid 36799595)
137. Lassota N, (2008): Clinical and histological aspects of CNV formation: studies in an animal model. Acta Ophthalmol 86 Thesis 2: 1-24.
138. Lee RC, Feinbaum RL, &, Ambros V, (1993): The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854. (Pubitemid 24014542)
139. Lee Y, Ahn C, Han J, et al. (2003): The nuclear RNase III Drosha initiates microRNA processing. Nature 425: 415-419. (Pubitemid 37187272)
140. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, &, Kim VN, (2004): MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23: 4051-4060. (Pubitemid 39472426)
141. Lee I, Ajay SS, Yook JI, et al. (2009): New class of microRNA targets containing simultaneous 5a€-UTR and 3a€-UTR interaction sites. Genome Res 19: 1175-1183.
142. Lee SH, Colosi P, Lee H, Ohn YH, Kim SW, Kwak HW, &, Park TK, (2013): Laser photocoagulation enhances adeno-associated virus vector transduction of mouse retina. Hum Gene Ther Methods 25: 83-91.
143. Lei J, Jiang A, &, Pei D, (1998): Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim Biophys Acta 1443: 400-406. (Pubitemid 29023374)
144. Levy NS, Chung S, Furneaux H, &, Levy AP, (1998): Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 273: 6417-6423. (Pubitemid 28144735)
145. Li CM, Chung BH, Presley JB, et al. (2005): Lipoprotein-like particles and cholesteryl esters in human Bruch's membrane: initial characterization. Invest Ophthalmol Vis Sci 46: 2576-2586. (Pubitemid 43119509)
146. Li L, Lin X, Khvorova A, Fesik SW, &, Shen Y, (2007): Defining the optimal parameters for hairpin-based knockdown constructs. RNA 13: 1765-1774. (Pubitemid 47481684)
147. Li Q, Miller R, Han PY, Pang J, Dinculescu A, Chiodo V, &, Hauswirth WW, (2008): Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis 14: 1760-1769.
148. Lopez PF, Grossniklaus HE, Lambert HM, Aaberg TM, Capone A Jr, Sternberg P Jr, &, L'Hernault N, (1991): Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 112: 647-656.
149. Lopez PF, Sippy BD, Lambert HM, Thach AB, &, Hinton DR, (1996): Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37: 855-868.
150. Lutty GA, Cao J, &, McLeod DS, (1997): Relationship of polymorphonuclear leukocytes to capillary dropout in the human diabetic choroid. Am J Pathol 151: 707-714. (Pubitemid 27385602)
151. Maclachlan TK, Lukason M, Collins M, et al. (2011): Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther 19: 326-334.
152. Maguire AM, Simonelli F, Pierce EA, et al. (2008): Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248. (Pubitemid 351724453)
153. Maguire AM, High KA, Auricchio A, et al. (2009): Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374: 1597-1605.
154. Maik-Rachline G, Shaltiel S, &, Seger R, (2005): Extracellular phosphorylation converts pigment epithelium-derived factor from a neurotrophic to an antiangiogenic factor. Blood 105: 670-678. (Pubitemid 40070751)
155. Majewski J, Schultz DW, Weleber RG, et al. (2003): Age-related macular degeneration-a genome scan in extended families. Am J Hum Genet 73: 540-550. (Pubitemid 37076268)
156. Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, &, Seddon JM, (2007): Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet 39: 1200-1201. (Pubitemid 47482689)
157. Martin JN, Wolken N, Brown T, Dauer WT, Ehrlich ME, &, Gonzalez-Alegre P, (2011): Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design. Gene Ther 18: 666-673.
158. McAnuff MA, Rettig GR, &, Rice KG, (2007): Potency of siRNA versus shRNA mediated knockdown in vivo. J Pharm Sci 96: 2922-2930. (Pubitemid 350221193)
159. McBride JL, Boudreau RL, Harper SQ, et al. (2008): Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105: 5868-5873. (Pubitemid 351758464)
160. Meyers SM, Greene T, &, Gutman FA, (1995): A twin study of age-related macular degeneration. Am J Ophthalmol 120: 757-766.
161. Miller H, Miller B, Ishibashi T, &, Ryan SJ, (1990): Pathogenesis of laser-induced choroidal subretinal neovascularization. Invest Ophthalmol Vis Sci 31: 899-908. (Pubitemid 20186101)
162. Mitchell P, Smith W, Attebo K, &, Wang JJ, (1995): Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 102: 1450-1460.
163. Miyazaki M, Ikeda Y, Yonemitsu Y, et al. (2011): Pigment epithelium-derived factor gene therapy targeting retinal ganglion cell injuries: neuroprotection against loss of function in two animal models. Hum Gene Ther 22: 559-565.
164. Mori K, Duh E, Gehlbach P, et al. (2001): Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 188: 253-263. (Pubitemid 32622916)
165. Mori K, Gehlbach P, Ando A, McVey D, Wei L, &, Campochiaro PA, (2002a): Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 43: 2428-2434. (Pubitemid 34700678)
166. Mori K, Gehlbach P, Yamamoto S, et al. (2002b): AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 43: 1994-2000. (Pubitemid 34587052)
167. Mullins RF, Russell SR, Anderson DH, &, Hageman GS, (2000): Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 14: 835-846. (Pubitemid 30241660)
168. Murakami Y, Ikeda Y, Yonemitsu Y, Miyazaki M, Inoue M, Hasegawa M, Sueishi K, &, Ishibashi T, (2010): Inhibition of choroidal neovascularization via brief subretinal exposure to a newly developed lentiviral vector pseudotyped with Sendai viral envelope proteins. Hum Gene Ther 21: 199-209.
169. Nagineni CN, Kommineni VK, William A, Detrick B, &, Hooks JJ, (2012): Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration. J Cell Physiol 227: 116-126.
170. Nan R, Gor J, Lengyel I, &, Perkins SJ, (2008): Uncontrolled zinc- and copper-induced oligomerisation of the human complement regulator factor H and its possible implications for function and disease. J Mol Biol 384: 1341-1352.
171. Natkunarajah M, Trittibach P, McIntosh J, Duran Y, Barker SE, Smith AJ, Nathwani AC, &, Ali RR, (2008): Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2/8. Gene Ther 15: 463-467. (Pubitemid 351331004)
172. Ng YS, Rohan R, Sunday ME, Demello DE, &, D'Amore PA, (2001): Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 220: 112-121. (Pubitemid 32107812)
173. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, &, Adamis AP, (2006): Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5: 123-132.
174. Nguyen QD, Schachar RA, Nduaka CI, et al. (2012): Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology 119: 1867-1873.
175. Notari L, Miller A, Martinez A, Amaral J, Ju M, Robinson G, Smith LE, &, Becerra SP, (2005): Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9: implications for downregulation in hypoxia. Invest Ophthalmol Vis Sci 46: 2736-2747. (Pubitemid 43086693)
176. Notari L, Baladron V, Aroca-Aguilar JD, et al. (2006): Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor. J Biol Chem 281: 38022-38037. (Pubitemid 46042106)
177. Nuzzi R, &, Tridico F, (2013): Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study. Seminars in ophthalmology. Informa Healthcare USA Inc, New York, NY, USA
178. Oh H, Takagi H, Takagi C, et al. (1999): The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 40: 1891-1898. (Pubitemid 29365148)
179. Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W, Zack DJ, &, Campochiaro PA, (1997): Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 151: 281-291.
180. Oshima Y, Oshima S, Nambu H, et al. (2004): Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J Cell Physiol 201: 393-400. (Pubitemid 39453125)
181. Park JE, Chen HH, Winer J, Houck KA, &, Ferrara N, (1994): Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 269: 25646-25654.
182. Park K, Lee K, Zhang B, Zhou T, He X, Gao G, Murray AR, &, Ma JX, (2011): Identification of a novel inhibitor of the canonical Wnt pathway. Mol Cell Biol 31: 3038-3051.
183. Parmeggiani F, Romano MR, Costagliola C, et al. (2012): Mechanism of inflammation in age-related macular degeneration. Mediators Inflamm 2012: 546786.
184. Parver LM, (1991): Temperature modulating action of choroidal blood flow. Eye (Lond) 5 (Pt 2): 181-185.
185. Pechan P, Rubin H, Lukason M, Ardinger J, DuFresne E, Hauswirth WW, Wadsworth SC, &, Scaria A, (2009): Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 16: 10-16.
186. Penfold PL, Killingsworth MC, &, Sarks SH, (1985): Senile macular degeneration: the involvement of immunocompetent cells. Graefes Arch Clin Exp Ophthalmol 223: 69-76. (Pubitemid 15051681)
187. Pennesi ME, Neuringer M, &, Courtney RJ, (2012): Animal models of age related macular degeneration. Mol Aspects Med 33: 487-509.
188. Petrs-Silva H, Dinculescu A, Li Q, et al. (2009): High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 17: 463-471.
189. Place RF, Li LC, Pookot D, Noonan EJ, &, Dahiya R, (2008): MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci USA 105: 1608-1613. (Pubitemid 351346562)
190. Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E, &, Neufeld G, (1997): VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 272: 7151-7158. (Pubitemid 27166421)
191. Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J, &, Jin Y, (2010): miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One 5: e9429.
192. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, &, Samulski RJ, (2002): Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76: 791-801. (Pubitemid 34033377)
193. Ramrattan RS, van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PG, &, de Jong PT, (1994): Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci 35: 2857-2864. (Pubitemid 24149800)
194. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J, &, Tolentino MJ, (2003): Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9: 210-216. (Pubitemid 38097589)
195. Robert L, (1998): Mechanisms of aging of the extracellular matrix: role of the elastin-laminin receptor. Gerontology 44: 307-317. (Pubitemid 28517491)
196. Roberts WG, &, Palade GE, (1995): Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108 (Pt 6): 2369-2379.
197. Robinson GS, Ju M, Shih SC, Xu X, McMahon G, Caldwell RB, &, Smith LE, (2001): Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. FASEB J 15: 1215-1217.
198. Rota R, Riccioni T, Zaccarini M, et al. (2004): Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J Gene Med 6: 992-1002. (Pubitemid 40228114)
199. Rudolf M, Clark ME, Chimento MF, Li CM, Medeiros NE, &, Curcio CA, (2008): Prevalence and morphology of druse types in the macula and periphery of eyes with age-related maculopathy. Invest Ophthalmol Vis Sci 49: 1200-1209.
200. Saint-Geniez M, Maharaj AS, Walshe TE, et al. (2008): Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS One 3: e3554.
201. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, &, D'Amore PA, (2009): An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA 106: 18751-18756.
202. Schubert S, Grunweller A, Erdmann VA, &, Kurreck J, (2005): Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions. J Mol Biol 348: 883-893. (Pubitemid 40544389)
203. Schwesinger C, Yee C, Rohan RM, et al. (2001): Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 158: 1161-1172. (Pubitemid 32221808)
204. Seddon JM, Ajani UA, &, Mitchell BD, (1997): Familial aggregation of age-related maculopathy. Am J Ophthalmol 123: 199-206. (Pubitemid 27066775)
205. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, &, Dvorak HF, (1983): Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985.
206. Shen H, Clauss M, Ryan J, et al. (1993): Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood 81: 2767-2773. (Pubitemid 23147585)
207. Shen J, Samul R, Silva RL, et al. (2006): Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 13: 225-234. (Pubitemid 43148645)
208. Sheraidah G, Steinmetz R, Maguire J, Pauleikhoff D, Marshall J, &, Bird AC, (1993): Correlation between lipids extracted from Bruch's membrane and age. Ophthalmology 100: 47-51. (Pubitemid 23041129)
209. Shima DT, Adamis AP, Ferrara N, Yeo KT, Yeo TK, Allende R, Folkman J, &, D'Amore PA, (1995): Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1: 182-193.
210. Shweiki D, Itin A, Neufeld G, Gitay-Goren H, &, Keshet E, (1993): Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Investig 91: 2235-2243. (Pubitemid 23141500)
211. Shweiki D, Neeman M, Itin A, &, Keshet E, (1995): Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 92: 768-772.
212. Siemerink MJ, Klaassen I, Van Noorden CJ, &, Schlingemann RO, (2013): Endothelial tip cells in ocular angiogenesis: potential target for anti-angiogenesis therapy. J Histochem Cytochem 61: 101-115.
213. Silva JM, Li MZ, Chang K, et al. (2005): Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 37: 1281-1288. (Pubitemid 41568714)
214. Simonelli F, Maguire AM, Testa F, et al. (2010): Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18: 643-650.
215. Singerman L, (2009): Combination therapy using the small interfering RNA bevasiranib. Retina 29: S49-S50.
216. Skeie JM, &, Mullins RF, (2009): Macrophages in neovascular age-related macular degeneration: friends or foes? Eye (Lond) 23: 747-755.
217. Soker S, Takashima S, Miao HQ, Neufeld G, &, Klagsbrun M, (1998): Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745. (Pubitemid 28155313)
218. Spencer KL, Hauser MA, Olson LM, et al. (2008): Deletion of CFHR3 and CFHR1 genes in age-related macular degeneration. Hum Mol Genet 17: 971-977. (Pubitemid 351426031)
219. Spranger J, Osterhoff M, Reimann M, et al. (2001): Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 50: 2641-2645. (Pubitemid 33733112)
220. Steen B, Sejersen S, Berglin L, Seregard S, &, Kvanta A, (1998): Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 39: 2194-2200. (Pubitemid 28455093)
221. Subramanian P, Notario PM, &, Becerra SP, (2010): Pigment epithelium-derived factor receptor (PEDF-R): a plasma membrane-linked phospholipase with PEDF binding affinity. Adv Exp Med Biol 664: 29-37.
222. Sugita S, Horie S, Yamada Y, &, Mochizuki M, (2010): Inhibition of B-cell activation by retinal pigment epithelium. Invest Ophthalmol Vis Sci 51: 5783-5788.
223. Surace EM, &, Auricchio A, (2008): Versatility of AAV vectors for retinal gene transfer. Vision Res 48: 353-359. (Pubitemid 351179513)
224. Testa F, Maguire AM, Rossi S, et al. (2013): Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 120: 1283-91.
225. Thakkinstian A, Han P, McEvoy M, Smith W, Hoh J, Magnusson K, Zhang K, &, Attia J, (2006): Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet 15: 2784-2790. (Pubitemid 44400405)
226. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, &, Kelly SP, (2005): Smoking and age-related macular degeneration: a review of association. Eye (Lond) 19: 935-944. (Pubitemid 43114972)
227. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, &, Abraham JA, (1991): The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 11947-11954.
228. Tobe T, Okamoto N, Vinores MA, Derevjanik NL, Vinores SA, Zack DJ, &, Campochiaro PA, (1998a): Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci 39: 180-188. (Pubitemid 28040477)
229. Tobe T, Ortega S, Luna JD, et al. (1998b): Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 153: 1641-1646. (Pubitemid 28509922)
230. Tombran-Tink J, &, Johnson LV, (1989): Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci 30: 1700-1707. (Pubitemid 19214990)
231. Tombran-Tink J, Lara N, Apricio SE, Potluri P, Gee S, Ma JX, Chader G, &, Barnstable CJ, (2004): Retinoic acid and dexamethasone regulate the expression of PEDF in retinal and endothelial cells. Exp Eye Res 78: 945-955. (Pubitemid 38402203)
232. Tsao YP, Ho TC, Chen SL, &, Cheng HC, (2006): Pigment epithelium-derived factor inhibits oxidative stress-induced cell death by activation of extracellular signal-regulated kinases in cultured retinal pigment epithelial cells. Life Sci 79: 545-550.
233. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, &, Speleman F, (2002): Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
234. Verzar F, (1957): The ageing of connective tissue. Gerontologia 1: 363-378.
235. Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, &, de Jong PT, (1995): The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 102: 205-210.
236. Wallace DC, (1999): Mitochondrial diseases in man and mouse. Science 283: 1482-1488.
237. Wang GL, &, Semenza GL, (1993): General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90: 4304-4308. (Pubitemid 23134215)
238. Wang J, Xu X, Elliott MH, Zhu M, &, Le YZ, (2010): Muller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes 59: 2297-2305.
239. Weber M, Rabinowitz J, Provost N, et al. (2003): Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol Ther 7: 774-781. (Pubitemid 36790254)
240. Wells JA, Murthy R, Chibber R, Nunn A, Molinatti PA, Kohner EM, &, Gregor ZJ, (1996): Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 80: 363-366. (Pubitemid 26113591)
241. Williams MA, McKay GJ, &, Chakravarthy U, (2014): Complement inhibitors for age-related macular degeneration. Cochrane Database Syst Rev 1: CD009300.
242. Yates JR, Sepp T, Matharu BK, et al. (2007): Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 357: 553-561. (Pubitemid 47236280)
243. Zamiri P, Masli S, Streilein JW, &, Taylor AW, (2006): Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest Ophthalmol Vis Sci 47: 3912-3918. (Pubitemid 46044306)
244. Zamiri P, Sugita S, &, Streilein JW, (2007): Immunosuppressive properties of the pigmented epithelial cells and the subretinal space. Chem Immunol Allergy 92: 86-93. (Pubitemid 47096898)
245. Zarbin MA, (2004): Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122: 598-614. (Pubitemid 38456297)
246. Zhang Y, Liu D, Chen X, et al. (2010): Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 39: 133-144.
247. Zhong L, Li B, Mah CS, et al. (2008): Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 105: 7827-7832. (Pubitemid 351872723)
248. Zhou H, Xia XG, &, Xu Z, (2005): An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res 33: e62.
249. Zincarelli C, Soltys S, Rengo G, &, Rabinowitz JE, (2008): Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16: 1073-1080. (Pubitemid 351737072)
250. Zweifel SA, Imamura Y, Spaide TC, Fujiwara T, &, Spaide RF, (2010): Prevalence and significance of subretinal drusenoid deposits (reticular pseudodrusen) in age-related macular degeneration. Ophthalmology 117: 1775-1781.